Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos, a drug discovery company, has announced that its service division BioFocus DPI has extended its drug discovery collaboration with Amgen through 2009 and 2010.
Subscribe to our email newsletter
BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen’s discovery programs.
Under the terms of the extended agreement, Galapagos will receive E2 million in research fees per year for two years. Additionally, Galapagos is eligible to receive compensation in the form of access fees and success-based milestones.
The collaboration, which was initiated in 2003 and extended in 2006, involves the identification of new molecules against drug targets from various protein classes, including ion channels, G protein-coupled receptors and kinases.
Chris Newton, senior vice president of BioFocus DPI, said: “We are pleased to extend our strong collaborative relationship with Amgen. We are looking forward to applying our screening expertise and unique compound libraries to continue to provide lead candidates for Amgen’s discovery programs over the next two years.”